Overview

Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Status:
Active, not recruiting
Trial end date:
2022-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand safety (e.g., occurrence of adverse drug reactions [ADRs]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter referred to as Vyndaqel) in all patients who received this drug under actual use conditions after its marketing.
Details
Lead Sponsor:
Pfizer